For two companies the FDA PRO Guidance leads to similar but different measures

A case study in psoriasis

Mordin, M., Brown, T., McLeod, L., DeMuro, C., & Gnanasakthy, A. (2015). For two companies the FDA PRO Guidance leads to similar but different measures: A case study in psoriasis. Value in Health, 18(3), A111-A111. https://doi.org/10.1016/j.jval.2015.03.653

Abstract

The objective of this research is to evaluate whether the 2009 FDA PRO Guidance leads to development of similar measures when followed by different researchers in the same disease. Psoriasis was selected as a case study, because two companies recently published patient-reported outcome measures to assess the severity of psoriasis-related symptoms: the Psoriasis Symptom Inventory (PSI) and the Psoriasis Symptom Diary (PSD).

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments
Article

The influence of mediators on the relationship between antenatal opioid agonist exposure and the severity of neonatal opioid withdrawal syndrome
Article

A scoping review of empirical research on prescription drug promotion